AstraZeneca’s Asthma Treatment Scores European Approval
The European Commission approved AstraZeneca Plc’s (NASDAQ:AZN) Tezspire (tezepelumab) as an add-on maintenance treatment for severe asthma. The approval covers patients…
Novartis To Petition US Supreme Court To Uphold Patent Validity For Multiple Sclerosis Drug, Gilenya
Swiss drug major Novartis AG (NYSE:NVS) plans to petition the U.S. Supreme Court to uphold the validity of the Gilenya (fingolimod) dosing…
FDA Concludes Oversight Shortcomings After Infant Formula Internal Review
The FDA concluded an internal review of agency actions related to the U.S. infant formula supply.
Cathie Wood Cuts Another $32M From Healthcare Company Following Amazon-Linked Rumors
Cathie Wood-led Ark Investment Management on Tuesday sold 1,102,797 shares in Signify Health Inc. (NYSE: SGFY), valued at $32.3 million, via two of its key exchange-traded funds.
Jupiter Wellness Seeks New Prescription Products For Issues In Breast Cancer Patients
Jupiter Wellness Inc (NASDAQ:JUPW) has signed an exclusive licensing agreement with Rejoy Inc to develop prescription products for the treatment of nipple neuropathies…
Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program
RBC Capital Markets raised the price target on Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) from $225 to $250. The analyst says that the company…
Satsuma Pharma Shares Are Gaining After Encouraging Update From Migraine Candidate
Satsuma Pharmaceuticals Inc (NASDAQ:STSA) announced favorable safety, tolerability, and efficacy results from its recent analysis of the ongoing STS101 ASCEND…
Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold
Merck & Co Inc (NYSE:MRK) will initiate a new Phase 3 program with once-daily islatravir to treat people with HIV-1 infection. …
United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease
United Therapeutics Corp (NASDAQ:UTHR) has terminated the Phase 3 PERFECT study evaluating Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension associated with…
Repligen Beefs Up Process Analytics Portfolio With DRS Daylight Solutions Pact
Repligen Corporation (NASDAQ:RGEN) entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of…